ANAB
Price
$46.66
Change
-$2.04 (-4.19%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
1.52B
19 days until earnings call
Intraday BUY SELL Signals
PBYI
Price
$9.82
Change
-$0.70 (-6.65%)
Updated
Oct 16, 04:59 PM (EDT)
Capitalization
506.91M
13 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

ANAB vs PBYI

ANAB vs PBYI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ANAB vs. PBYI commentary
Oct 17, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ANAB is a Hold and PBYI is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ANAB with price predictions
Oct 15, 2026

ANAB in upward trend: price expected to rise as it breaks its lower Bollinger Band on September 23, 2026

ANAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 30 cases where ANAB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANAB's RSI Oscillator exited the oversold zone, 17 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where ANAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ANAB as a result. In 79 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.

The Moving Average Convergence Divergence (MACD) for ANAB just turned positive on October 15, 2026. Looking at past instances where ANAB's MACD turned positive, the stock continued to rise in 44 of 53 cases over the following month. The odds of a continued upward trend are 83%.

Following a +6.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in 226 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

The Aroon Indicator for ANAB entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (142.857) is normal, around the industry mean (26.782). P/E Ratio (97.087) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.614) is also within normal values, averaging (437.542).

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
a Summary for PBYI with price predictions
Oct 15, 2026

Momentum Indicator for PBYI turns positive, indicating new upward trend

PBYI saw its Momentum Indicator move above the 0 level on October 07, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In 89 of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for PBYI just turned positive on October 09, 2026. Looking at past instances where PBYI's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.

Following a +3.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in 259 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.

The Aroon Indicator entered an Uptrend today. In 199 of 227 cases where PBYI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

PBYI broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.659) is normal, around the industry mean (26.782). P/E Ratio (19.275) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (2.105) is also within normal values, averaging (437.542).

FUNDAMENTALS RATINGS
ANAB vs PBYI: Fundamental Ratings
ANAB
PBYI
OUTLOOK RATING
1..100
5741
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
74
Overvalued
PROFIT vs RISK RATING
1..100
3761
SMR RATING
1..100
9944
PRICE GROWTH RATING
1..100
4336
P/E GROWTH RATING
1..100
614
SEASONALITY SCORE
1..100
7536

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PBYI's Valuation (74) in the Biotechnology industry is in the same range as ANAB (96). This means that PBYI’s stock grew similarly to ANAB’s over the last 12 months.

ANAB's Profit vs Risk Rating (37) in the Biotechnology industry is in the same range as PBYI (61). This means that ANAB’s stock grew similarly to PBYI’s over the last 12 months.

PBYI's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for ANAB (99). This means that PBYI’s stock grew somewhat faster than ANAB’s over the last 12 months.

PBYI's Price Growth Rating (36) in the Biotechnology industry is in the same range as ANAB (43). This means that PBYI’s stock grew similarly to ANAB’s over the last 12 months.

PBYI's P/E Growth Rating (4) in the Biotechnology industry is somewhat better than the same rating for ANAB (61). This means that PBYI’s stock grew somewhat faster than ANAB’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ANABPBYI
RSI
ODDS (%)
Bullish Trend 2 days ago
81%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
89%
Declines
ODDS (%)
Bearish Trend 10 days ago
81%
Bearish Trend 15 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
78%
Aroon
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
88%
COMPARISON
Comparison
Oct 17, 2026
Stock price -- (ANAB: $48.71 vs. PBYI: $10.52)
Brand notoriety: ANAB and PBYI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ANAB: 89% vs. PBYI: 116%
Market capitalization -- ANAB: $1.52B vs. PBYI: $506.91M
ANAB [@Biotechnology] is valued at $1.52B. PBYI’s [@Biotechnology] market capitalization is $506.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ANAB’s FA Score shows that 0 FA rating(s) are green while PBYI’s FA Score has 1 green FA rating(s).

  • ANAB’s FA Score: 0 green, 5 red.
  • PBYI’s FA Score: 1 green, 4 red.
According to our system of comparison, PBYI is a better buy in the long-term than ANAB.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ANAB’s TA Score shows that 6 TA indicator(s) are bullish while PBYI’s TA Score has 4 bullish TA indicator(s).

  • ANAB’s TA Score: 6 bullish, 2 bearish.
  • PBYI’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, ANAB is a better buy in the short-term than PBYI.

Price Growth

ANAB (@Biotechnology) experienced а +5.41% price change this week, while PBYI (@Biotechnology) price change was +5.52% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -10.70%. For the same industry, the average monthly price growth was -18.24%, and the average quarterly price growth was -21.46%.

Reported Earning Dates

ANAB is expected to report earnings on Nov 04, 2026.

PBYI is expected to report earnings on Oct 29, 2026.

Industries' Descriptions

@Biotechnology (-10.70% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.